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Cyclophosphamide for Clinical Renal and Hepatic Transplantation 
By T. E. Starzl, C. G. Groth, C. W. Putnam, J. Corman, C. G. Halgrimson, 
I. Penn, B. Husberg, A. Gustafsson, S. Cascardo, P. Geis, and S. Iwatsuki 
SINCE March, 1971, cyclophosphamide (Cytoxan) has had a prominent role in 
the immunosuppression administered to 
recipients of whole organs at our center. 
This report will be concerned with the 
results in these patients, about two-thirds 
of whom now have a potential follow-up 
of more than 1 yr. 
MATERIALS AND METHODS 
Renal Homotransplantation 
From Related Donors: Donors for 32 recip-
ients included 16 siblings (six were double haplo-
type HL-A identical), 14 parents, one aunt, and 
one grandmother. Except for the search for HL-A-
identical siblings, the results of HL-A matching 
were not given weight in donor selection. An at-
tempt was made to avoid transplantation when 
the crossmatch was positive for cytotoxic anti-
bodies. However, in one case, such antibodies 
developed in the period between testing and opera-
tion with a resulting hyperacute rejection. 
Cyclophosphamide, prednisone, and horse anti-
lymphocyte globulin (ALG) were started several 
days in advance of operation and continued after-
wards in various modifications of the general 
regimen described in detail eisewhere L2 and 
shown in Figs. 1 and 2. Postoperatively, ALG was 
usually continued for 2-4 mo. 
Before September 1971 most patients were 
treated with cyclophosphamide for many months 
after which a change was eventually made in 
almost every case to maintenance therapy with 
azathioprine (Fig. 1). In contrast, patients treated 
in the last 3 mo of the study (October to Decem-
ber 1971) had a shorter course of cyclophospha-
mide therapy (1-2 mo) before switching to aza-
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thioprine (Fig. 2). Doses of cyclophosphamide in 
milligram per kilogram body weight were usually 
one-half to two-thirds those later employed with 
azathioprine. With either of these potentially 
radiomimetic agents, an effort was made to avoid 
leukopenia. 
Cadaveric Transplantation: The crossmatch 
test for cytotoxic antibodies was negative in all 
cases. HL-A typing was performed, but since the 
results were not taken into consideration for 
donor-recipient pairing, all recipients were given 
more or less badly matched kidneys (5 C, 10 D, 
and 18 E)*. 
Therapy after cadaveric transplantation was 
similar to that after consanguineous transplanta-
tion except that immunosuppressive pretreatment 
was not feasible. The cadaveric recipients, by and 
large, presented more complicated problems of 
management than did related cases. Their average 
age was 33 ± 12.7 (SD) yr as opposed to 27 ± 
11.2 (SD) yr for the consanguineous recipients. In 
addition whereas only one of the 32 recipients of 
related kidneys was undergoing retransplantation, 
nine of the 29 cadaveric recipients had already re-
jected one or more homografts at some previous 
time. 
Hepatic Homotransplantation 
There were 16 patients, aged 1-53 yr, who 
received orthotopic hepatic homo grafts from 2-19 
mo ago and who were treated with a cyclophos-
phamide-containing, triple drug regimen similar 
to that used for recipients of cadaveric kidneys 
(Fig. 3). The indications for liver replacement were 
biliary atresia (seven cases), chronic aggressive 
hepatitis (four cases), biliary cirrhosis (three 
cases), Wilson's disease (one case) and hepatic 
hemangioendothelial sarcoma (one case). 
RESULTS 
From Related Donors (Table 1): Three 
(9.4%) of the 32 recipients died, 2 from 
Pneumocystis carinii pneumonia, and the 
*C = one mismatched HL-A antigen; D = 
one mismatch of each HL-A locus; E = double 
mismatch at one HL-A locus, usually with mis-
matches at other locus as well. 
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Fig. 1. The chronic use of cyclophosphamide in conjunction with prednisone and early 
ALG in the recipient of a parental renal homograft. Treatment was changed to aza-
thioprine after 10 mo, with an increase in the milligram per day dose. The patient has a 
perfect result after 11/2 yr. 
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Fig. 2. The use of cyclophosphamide for the first postoperative month with subsequent 
azathioprine treatment. The result was excellent after almost a year. 
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Table 1. Results with Renal Homotransplantation: 
Follow-up 9-18 Months 
Total Lost 
Donor Number Per cent 
Consanguineous 
Patients 32 3 9.4 
Grafts 32 6 18.8 
Cadaveric 
Patients 29 7' 24.1 
Grafts 33 11' 33.3 
'Four of the seven deaths and seven of the 11 
graft losses were in nine patients undergoing 
retransplantation. 
third from perforation of a sigmoid colonic 
diverticulum. Three additional grafts were 
lost, two from hyperacute rejection and one 
from a technical surgical accident, for a 
total kidney loss rate of 6 in 32 (18.8%). 
From 9-18 mo post-transplantation, the 
remaining 26 consanguineous renal homo-
grafts have average functions as follows: 
BUN 25.6 :!: 10.3 (SO) mg/mt and creati-
nine clearance 70.9 :!: 20.4 (SO) mllmin. 
The clinical result is presently considered 
excellent with 24 of these 26 kidneys and 
fair in the other two. 
Cadaveric Transplantation (Table 1): 
Seven (24%) of the 29 recipients died; all 
but 1 from causes that were apparently 
directly related to immunosuppression. 
These included brain tumor (glioblastoma 
multiforme), hindquarter gangrene due to 
Pseudomonas, a fungal brain abscess (As-
pergillus), Pneumocystis carinii pneumo-
nitis, perforated sigmoid diverticulitis and 
giant cecal ulcer. The seventh patient died 
of a recently described complication of 
hyperparathyroidism-consisting of wide-
spread skin and muscle gangrene appar-
ently due to calcium plugging of multiple 
small arteries.3 There were four deaths 
(44 %) among the 9 patients undergoing 
ertransplantation (after a previous graft 
had been in residence for 1 hr to 5 yr, 
average 18 mol compared to three (15%) 
among the 20 receiving primary homo-
grafts. 
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The 29 recipients of cadaver kidneys 
were given 33 transplants. Two of the four 
extra organs were used in the classic se-
quence after the initial grafts had been 
rejected and removed but in the other 2 
cases second transplants were inserted 11/2 
and 5 wk after the first because of poor 
initial function. In these latter recipients, 
both the first and second homo grafts even-
tually functioned for long periods. 
Twenty-two of the 33 grafts (67%) are 
still functioning after 9-18 mo. The 11 lost 
organs failed for the following reasons: 
Seven from recipient death; two from un-
controlled rejection; one from hyperacute 
rejection; and one because it was removed 
for wound pain 14 mo post-transplantation 
(one of the double homografts described in 
the preceding paragraph). 
Twenty-one of the 22 surviving patients 
have life-supporting urine excretion, the 
exceptional patient being back on dialysis. 
The homografts have average function as 
follows: BUN 26.1 :!: 10.2 (SO) mg/ml and 
creatinine clearance 67.9 :!: 23.3 (SO) mll 
min. The clinical result is currently con-
sidered excellent or good in 19 of these 21 
survivors who bear functioning grafts, fair 
in one, and poor in one. 
Liver Homotransplantation 
Nine of the 16 recipients of hepatic 
homografts died after 2-87 days. Causes 
of failure were biliary tract obstruction 
(three cases), biliary fistula (two cases), 
homograft rejection (two cases), acute liver 
infarction (one case), and tumor recurrence 
(one case). All five patients with biliary 
tract complications succumbed, four of sep-
sis in spite of surgical correction of the 
lesion and/or drainage, and the fifth after 
an attempt at retransplantation. 
Seven patients are alive 18, 14, 7, 5, 5, 4, 
and 2 mo after transplantation for Wilson's 
disease (one case), biliary atresia (one 
case), congenital biliary cirrhosis (two 
cases), and chronic aggressive hepatitis 
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(three cases). One of the patients has mod-
erate hepatic dysfunction due to chronic 
rejection at 14 months (bilirubin 2 mg%) 
and the other six have normal or near 
normal liver function. 
DISCUSSION 
In this communication, most of the case 
material consisted of patients who received 
cyclophosphamide as the initial cytotoxic 
agent in a triple drug program with the 
frequent later substitution of azathioprine. 
In previous publications,1.2 considerable 
experience was reported with the reverse 
order of administration, using cyclophos-
phamide to replace azathioprine. Under 
both circumstances, cyclophosphamide has 
seemed equivalent to azathioprine in its 
toxicity as well as in its immunosuppressive 
effectiveness. 
It is of interest that in kidney recipients 
two drugs belonging to such different 
chemical families and having such fund a-
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mentally different modes of action as 
cyclophosphamide and azathioprine can be 
substituted freely for each other. It re-
mains to be seen if switching agents will 
have real benefits such as, for example, if 
the depletion of sensitized immunocom-
petent cells was more effective. At the 
moment, this remains a possibility, but one 
which has by no means been proven. 
In the therapeutic program that has 
evolved during the last 18 months and is 
now in routine use, cyclophosphamide has 
been used as the first-line agent for 2 mo or 
for whatever fraction of that time during 
which doses of at least 1 mg/kg/ day can 
be tolerated without bone marrow depres-
sion. Even in these small quantities, cyclo-
phosphamide may cause leukopenia, in 
which case the substitution of azathioprine 
is made prematurely. 
Using this manipulation of the cyclo-
phosphamide-azathioprine complex in a 
system that also includes prednisone and 
te~ht 50 ~ 46 K. 
15 year old r:i 
2 
l++~~==~~~~--------~~~~=-==~~-=~--~~~ 
200 
~ CYCLOPHOSPHAMIDE 150 
CJ AZATHIOPRINE 100 
(mg/day) 50 
o 
200 
PREDNISONE 150 
(mg/day) 100 
ALG 
(4 ee) 
50 
o 
AUSTRALIAN ANTIGEN (CF) ® 
iii i I 
-20 8 16 24 32 40 48 56 64 72 80 88 96 104 140 200 260 320380 
TIME IN DAYS 
Fig. 3. Triple drug treatment, including cyclophosphamide, in an orthotopic liver 
recipient. No rejection was diagnosed, but serum hepatitis in the second and third 
postoperative months caused jaundice. After 9 mo, azathioprine was substituted for 
cyclophosphamide. 
CYCLOPHOSPHAMIDE 
ALG, patient and graft-survival in renal 
cases have been essentially the same as 
with the precyclophosphamide triple-drug 
combination of azathioprine, prednisone, 
and ALG.2 The quality of graft function in 
the cyclophosphamide-treated patients has 
been at least as good and possibly even 
superior. 
In analyzing results with immunosup-
pressive programs in the modern era of 
transplantation, more than passing con-
sideration must be given to the increasing 
complexity of case material, which is going 
to make it difficult to achieve results as 
good as those obtained in highly selected 
series of a few years ago. More and more, 
candidates are being accepted who, until 
recently, would have been excluded because 
of age, associated diseases, or other rea-
sons. In addition, a third of all cadaveric 
renal homografts in the present report were 
used for retransplantation under conditions 
which proved to have a very high risk 
(44% mortality). In contrast, patients 
receiving primary cadaveric homografts 
faced only a 15% mortality, approximately 
the same with 9-18-mo follow-ups as with 
consanguineous transplantation. 
The essential equivalency of results after 
renal transplantation under primary cyclo-
phosphamide, as opposed to azathioprine 
therapy, will not be a strong inducement 
for other groups, mainly interested in the 
kidney, to change their present regimen of 
azathioprine management, except for spe-
cific indications such as drug hepatoxicity. 
But with liver transplantation, future pos-
sibilities are more expansive. The disad-
vantages of azathioprine for liver trans-
plantation have been well recognized, in-
cluding its potential hepatotoxicity, as well 
as its dependence upon liver function for 
both activation and degradation.4 ,5 Re-
cently, Bach and Dardenne6 ,7 have pro-
vided striking evidence, with the rosette 
inhibition bioassay, that azathioprine loses 
its immunosuppressive qualities in human 
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tion. Their work has been confirmed in 
human liver recipients by Mitchell et al.B 
beings if there is significant liver malfunc-
If, as seems likely from Bach's data, the 
rosette inhibition test is a discriminating 
bioassay of immunosuppression, hepatic 
damage from ischemia, rejection, or other 
causes could cancel the efficacy of aza-
thioprine at a crucial time, especially early 
postoperatively. This could explain why 
rejection has been so difficult to control 
in human liver recipients, particularly 
when ALG has been omitted,5 in spite 
of impressive evidence from animal re-
search4,5,9-11 that the liver should be "eas-
ier" than other organs. It is possible that 
the potency of cyclophosphamide is simi-
larly turned off during hepatic dysfunction, 
since cyclophosphamide is also activated in 
the liver. Studies of rosette inhibition dur-
ing cyclophosphamide treatment, to settle 
this question, will be of great interest. 
Our experience with cyclophosphamide 
is consistent with the hypothesis that this 
drug retains sufficient potency throughout 
variations in postoperative hepatic func-
tion. During the learning period, mistakes 
in cyclophosphamide dosage, technical sur-
gical complications, and recurrence of ma-
lignancy caused several deaths. Neverthe-
less, seven of 16 patients (44%) are still 
alive, including five of the six recipients 
treated in the present year. This last group 
is the best consecutive series of liver cases 
we have ever seen and may herald the 
transition of hepatic transplantation from 
clinical investigation to true patient service. 
SUMMARY 
Cyclophosphamide was given as the 
initial cytotoxic drug in combination with 
prednisone and ALG to 61 renal recipients. 
After 1 mo or longer, azathioprine was sub-
stituted for cyclophosphamide for mainte-
nance therapy. After 9-18 mo, the patient 
and kidney survivals with consanguineous 
transplantation are 91 % and 81 %, respec-
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tively, and after cadaveric renal transplan-
tation the figures are 76% and 67%, 
respectively. These results are similar to 
those obtained in the past with azathio-
prine alone. 
Sixteen recipients of orthotopic cadaveric 
livers were similarly treated with seven 
(44%) living after 2-18 mo. With avoid-
ance of technical accidents and increased 
experience with cyclophosphamide, the 
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record since January 1972 is five survivors 
of six. In these patients, little difficulty 
was encountered with control of rejection. 
This observation, plus recent evidence that 
azathioprine may not be immunosuppres-
sive in patients with significant hepatic dys-
function, suggests that cyclophosphamide 
is the preferable primary cytotoxic drug 
for the early treatment of liver recipients. 
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